Skip to main content

News

BPL Full Year 2021 Results: BPL delivers another strong performance

07 February 2022

Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the 12 months ended 31 December 2021, including the more recent developments since first half trading update issued in July.

Read full article

BPL affiliate makes first ever sale to Mexico

04 February 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced its first ever direct sale in Mexico as part of an important supply award of Zenalb® 20%.

Read full article

BPL granted licence from the National Medical Products Administration (NMPA) to market ALBUMINEX® 25% product to China

24 January 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX® 25% product to China.

Read full article

PERMIRA FUNDS TO PARTNER WITH MARCUCCI FAMILY TO INVEST IN KEDRION BIOPHARMA AND BIO PRODUCTS LABORATORY

20 January 2022

20 January 2022 – Permira, the global private equity firm, today announces that funds advised by Permira, supported by their co-investor, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), have entered into a partnership with Kedrion’s existing shareholders (the Marcucci family and FSI) to jointly acquire and combine Kedrion and BPL. The combination will create a global player for medicines derived from human blood plasma, which treat patients with rare and life threatening conditions.

Read full article

BPL to support the Immune Deficiency Foundation Research Grant Program

22 October 2021

The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (P.I.), including well-defined research projects with a specified benefit for improving the treatment, health, disease management, or diagnosis of people with P.I. management or diagnosis of people with primary immunodeficiency diseases.

Read full article

Second Annual Hereditary Factor 10 Deficiency Awareness Day Kicks Off October 10

08 October 2021

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, is proud to partner with the National Hemophilia Foundation in recognizing the second Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2021.

Read full article

BPL Announces the Kick-off of the Hereditary Factor X Deficiency in America Survey

28 September 2021

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US offices in Durham, NC announced today, the kick-off of the Hereditary Factor X Deficiency in America Survey, the first of its kind focusing on patients suffering from this ultra-rare bleeding disorder.

Read full article

BPL 1st Half 2021 Results: BPL delivers a strong performance

21 July 2021

Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the six months ending 30 June 2021. BPL is a vertically integrated manufacturer of plasma-derived medicinal products headquartered in Elstree, UK. BPL consists of two divisions, BPL Plasma, based in Texas, which collects plasma from 26 centres across the US, and BPL Therapeutics in the UK, which manufactures high-quality products.

Read full article

BPL celebrates World Blood Donor Day and the essential contribution of its plasma donors in providing critical therapies worldwide

14 June 2021

Bio Products Laboratory (“BPL”), a specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, celebrates World Blood Donor Day (“WBDD”) in recognition of the critical role of donors worldwide in enhancing and saving lives.

Read full article